Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository

JERUSALEM, October 23 /PRNewswire-FirstCall/ --
- An Insulin Suppository Represents an Important Development in the
Treatment of Diabetes as it Provides a Painless Alternative for Effective
Insulin Delivery
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; http://www.oramed.com), a
developer of alternative drug delivery systems, announced today that it has
received approval from the South Africa Medicines Control Council (MCC) to
begin conducting Phase 1A trials on eight healthy human volunteers for ORMD
0802, the company's newly developed insulin suppository.
Oramed's Phase 1A trials on its insulin suppository mark an important
step in the history of insulin delivery as it will provide a painless option
for diabetics who seek an alternative to current delivery methods. An insulin
suppository is especially important for small children and seniors, who often
struggle with injections.
"The Phase 1A trial of our insulin suppository is a natural expansion of
Oramed's pursuit and development of alternative insulin delivery systems,"
said Oramed's CEO, Nadav Kidron. "By creating an insulin suppository, Oramed
hopes to ensure that diabetics will be able to receive insulin in the form
which is most suitable to their lifestyle and/or age."
This Phase 1A trial follows Oramed's announcement of its successful Phase
2A clinical trials on its oral insulin capsule, ORMD 0801, which demonstrated
that the product has a strong safety profile and was well tolerated, as well
as being effective in lowering blood glucose levels, in patients with type 2
diabetes.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top research scientists at Jerusalem's Hadassah
Medical Center. The Company's corporate and R&D headquarters are based in
Jerusalem.
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of the company
to differ materially from those expressed or implied in such forward looking
statements. The company undertakes no obligation to update or revise any
forward-looking statements.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals
Eric Rosenberg
Cell: +972-54-566-7713
Office: +972-2-566-0001
Email: eric@oramed.com

Media Contacts:
Ruder Finn Israel for Oramed
Matthew Krieger
Cell: +972-54-467-6950
Office: +972-2-589-2003
Email: matthew@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Company and Investor Relation Contacts:, Oramed Pharmaceuticals, Eric
Rosenberg, Cell: +972-54-566-7713, Office: +972-2-566-0001, Email:
eric@oramed.com; Media Contacts:, Ruder Finn Israel for Oramed, Matthew
Krieger, Cell: +972-54-467-6950, Office: +972-2-589-2003, Email:
matthew@oramed.com